FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships

January 12th 2026

By Skylar Jeremias

Real-World Study Finds Stable Vision After Switch to Ranibizumab Biosimilar

January 7th 2026

By Skylar Jeremias

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective solution for long-term management.

Evidence Supports Safe, Effective Switching to Etanercept Biosimilars

January 6th 2026

By Skylar Jeremias

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for chronic inflammatory diseases.

FDA Approves Amneal Denosumab Biosimilars, Capping Year of Market Expansion

January 6th 2026

By Skylar Jeremias

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving competition and cost savings.

Evidence Gaps Continue to Shape Biosimilar Adoption in Pediatric Care

January 5th 2026

By Skylar Jeremias

There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the need for more robust data.

Biosimilar Market Momentum: EU Approvals, Strategic Launches, and Major US Partnerships

January 2nd 2026

By Skylar Jeremias

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone health markets.

Top 5 Most-Read Biosimilar News of 2025

December 31st 2025

By Skylar Jeremias

Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends shaping patient access in 2025.

Top 5 Most-Read Gastroenterology Articles of 2025

December 29th 2025

By Skylar Jeremias

Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics impacting IBD treatment options.

Top 5 Most-Read Ophthalmology Articles of 2025

December 26th 2025

By Skylar Jeremias

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data.

Top 5 Most-Read Bone Health Articles of 2025

December 24th 2025

By Skylar Jeremias

Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in 2025.